PL1765388T3 - Terapia skojarzona do zapobiegania chorobie Alzheimera lub leczenia tej choroby oraz zestaw do tego celu - Google Patents

Terapia skojarzona do zapobiegania chorobie Alzheimera lub leczenia tej choroby oraz zestaw do tego celu

Info

Publication number
PL1765388T3
PL1765388T3 PL05767978T PL05767978T PL1765388T3 PL 1765388 T3 PL1765388 T3 PL 1765388T3 PL 05767978 T PL05767978 T PL 05767978T PL 05767978 T PL05767978 T PL 05767978T PL 1765388 T3 PL1765388 T3 PL 1765388T3
Authority
PL
Poland
Prior art keywords
disease
preventing
combination therapy
treating alzheimer
kit therefor
Prior art date
Application number
PL05767978T
Other languages
English (en)
Inventor
Franck Mattner
Walter Schmidt
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of PL1765388T3 publication Critical patent/PL1765388T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
PL05767978T 2004-07-13 2005-07-06 Terapia skojarzona do zapobiegania chorobie Alzheimera lub leczenia tej choroby oraz zestaw do tego celu PL1765388T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0118504A AT500483B1 (de) 2004-07-13 2004-07-13 Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
PCT/EP2005/053224 WO2006005706A2 (de) 2004-07-13 2005-07-06 Kombinationstherapie zur vorbeugung oder behandlung der alzheimer´schen erkrankung sowie kit hierfür
EP05767978.9A EP1765388B8 (de) 2004-07-13 2005-07-06 Kombinationstherapie zur vorbeugung oder behandlung der alzheimerschen erkrankung sowie set hierfür

Publications (1)

Publication Number Publication Date
PL1765388T3 true PL1765388T3 (pl) 2013-09-30

Family

ID=35115768

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05767978T PL1765388T3 (pl) 2004-07-13 2005-07-06 Terapia skojarzona do zapobiegania chorobie Alzheimera lub leczenia tej choroby oraz zestaw do tego celu

Country Status (15)

Country Link
US (2) US7935348B2 (pl)
EP (1) EP1765388B8 (pl)
JP (2) JP5642333B2 (pl)
KR (1) KR101158600B1 (pl)
CN (1) CN101022825B (pl)
AT (1) AT500483B1 (pl)
AU (1) AU2005261687B8 (pl)
CA (1) CA2577332C (pl)
DK (1) DK1765388T3 (pl)
ES (1) ES2414872T3 (pl)
HK (1) HK1103354A1 (pl)
PL (1) PL1765388T3 (pl)
PT (1) PT1765388E (pl)
TW (1) TW200602072A (pl)
WO (1) WO2006005706A2 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
MX2009006685A (es) * 2006-12-22 2009-07-27 Genentech Inc Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos.
EP2486928A1 (en) * 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2226081A4 (en) * 2007-10-25 2011-10-12 Univ Kagoshima PEPTIDE VACCINE WITH A MIMIC MOLECULE OF AMYLOID PEPTIDE
ES2332846B1 (es) 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
AT509611B1 (de) * 2008-06-12 2012-04-15 Affiris Forschungs-Und Entwicklungs Gmbh Vakzin
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
WO2010014702A1 (en) * 2008-07-29 2010-02-04 Medtronic, Inc. Apheresis of a target molecule from cerebrospinal fluid
CA2742771A1 (en) * 2008-11-13 2010-05-20 Modgene, Llc Modification of amyloid-beta load in non-brain tissue
WO2010073580A1 (ja) 2008-12-22 2010-07-01 学校法人藤田学園 Aβ除去材、Aβ除去器及びAβ除去システム
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
JP5843345B2 (ja) 2010-07-08 2016-01-13 旭化成メディカル株式会社 β−アミロイド除去システム
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
ES2496341T3 (es) 2011-10-04 2014-09-18 Affiris Ag Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica
US9707231B2 (en) 2011-11-01 2017-07-18 Modgene, Llc Compositions and methods for reduction of amyloid-beta load
CN110133299A (zh) * 2012-03-18 2019-08-16 株式会社资生堂 疾病样品分析装置、分析系统及分析方法
EP2834643B1 (de) 2012-04-05 2019-10-23 Forschungszentrum Jülich GmbH Verfahren zur behandlung von blut, blutprodukten und organen
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
WO2013150127A2 (de) 2012-04-05 2013-10-10 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
WO2015135942A1 (en) * 2014-03-11 2015-09-17 Universite D'aix-Marseille A chimeric peptide that interacts with cell membrane gangliosides
CN106466298A (zh) * 2015-08-14 2017-03-01 上海交通大学医学院 一种单唾液酸四己糖神经节苷脂修饰的重组脂蛋白及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476715A (en) 1989-10-03 1995-12-19 Fresenius Ag Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits
WO1995031727A1 (en) 1994-05-13 1995-11-23 Therasorb Medizinische Systeme Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
EP0886085B1 (en) 1997-06-18 2002-04-03 Morse Tec Europe S.p.A. Sprocket wheel with improved tooth profile for greater silentness
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP2002533169A (ja) 1998-12-29 2002-10-08 オキュロジックス コーポレイション レオロジー的処置方法および関連するアフェレーシスシステム
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
DE60217107T2 (de) 2001-06-20 2007-08-23 Ramot At Tel Aviv University Ltd. Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
WO2003051374A2 (en) * 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
AU2003250102B2 (en) * 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
AU2003303198A1 (en) * 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
WO2004069182A2 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
AT413336B (de) 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament

Also Published As

Publication number Publication date
TWI350173B (pl) 2011-10-11
JP2008506665A (ja) 2008-03-06
EP1765388B8 (de) 2013-05-29
AT500483B1 (de) 2006-01-15
PT1765388E (pt) 2013-05-24
KR101158600B1 (ko) 2012-07-09
AU2005261687A1 (en) 2006-01-19
KR20070036158A (ko) 2007-04-02
US7935348B2 (en) 2011-05-03
AU2005261687B8 (en) 2011-07-21
HK1103354A1 (en) 2007-12-21
WO2006005706A3 (de) 2006-07-20
CN101022825A (zh) 2007-08-22
CA2577332A1 (en) 2006-01-19
CN101022825B (zh) 2015-02-04
EP1765388B1 (de) 2013-04-17
WO2006005706A8 (de) 2006-11-16
ES2414872T8 (es) 2014-11-06
ES2414872T3 (es) 2013-07-23
US20110201987A1 (en) 2011-08-18
WO2006005706A2 (de) 2006-01-19
AT500483A4 (de) 2006-01-15
EP1765388A2 (de) 2007-03-28
US20080051690A1 (en) 2008-02-28
JP2013116903A (ja) 2013-06-13
JP5642333B2 (ja) 2014-12-17
CA2577332C (en) 2014-12-09
TW200602072A (en) 2006-01-16
AU2005261687B2 (en) 2011-02-17
DK1765388T3 (da) 2013-07-22

Similar Documents

Publication Publication Date Title
PL1765388T3 (pl) Terapia skojarzona do zapobiegania chorobie Alzheimera lub leczenia tej choroby oraz zestaw do tego celu
HK1216080A1 (zh) 用於治療或預防草酸鹽相關疾病的組合物和方法
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
EP1745060A4 (en) COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND FOR THE INHIBITION OF AMYLOID BETA PEPTIDE PRODUCTION
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
GB0316912D0 (en) Therapeutic treatment
EP1731113A4 (en) MEDICAL TREATMENT KIT
AU2003220096A8 (en) Methods for alzheimer's disease treatment and cognitive enhancement
EP1656359A4 (en) MACROCYCLIC BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
GB0320806D0 (en) Therapeutic treatment
GB0329275D0 (en) Therapeutic treatment
GB0307863D0 (en) Therapeutic treatment
GB0313772D0 (en) Therapeutic treatment
EP1701736A4 (en) THERAPEUTIC AGENTS AND ITS USES
GB0425854D0 (en) Therapeutic treatment
AU2003230848A8 (en) Methods and compositions for treating alzheimer's disease
GB2397018B (en) Combination therapy for treating disease
GB0316641D0 (en) Leather treatment
SI1679319T1 (sl) Postopki za preprecevanje in zdravljenje Alzheimerjeve bolezni
GB0408752D0 (en) Therapeutic treatment
GB0318552D0 (en) Therapeutic treatment
GB0300881D0 (en) Therapeutic treatment
GB0321233D0 (en) Therapeutic treatment
GB0322000D0 (en) Therapeutic treatment
GB0321236D0 (en) Therapeutic treatment